Barrett Asset Management’s AstraZeneca AZN Stock Holding History

Barrett Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-165	Closed	-$19K	–	244
2021 Q4	$19K	Buy	165 +90	+120%	+$10.6K	﹤0.01%	493
2021 Q3	$9K	Buy	+75	New	+$8.73K	﹤0.01%	423
2020 Q3	–	Sell	-225	Closed	-$24K	–	380
2020 Q2	$24K	Buy	+225	New	+$23.2K	﹤0.01%	291

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Barrett Asset Management's AZN Position: Q1 2022 in Review

Barrett Asset Management sold out of AstraZeneca (AZN) in Q1 2022, closing a stake of 165 shares — an estimated $19K sold.

Barrett Asset Management first reported a position in AZN in Q2 2020 and held it in 3 quarters. The position peaked at $24K in Q2 2020. 982 funds tracked by Wall St. Rank hold AZN as of Q1 2022.

Barrett Asset Management reported no remaining AstraZeneca position as of Q1 2022 after selling out during the quarter.
Barrett Asset Management sold 165 AstraZeneca shares in Q1 2022, an estimated $19K.
Barrett Asset Management first reported a position in AstraZeneca in Q2 2020 and held it in 3 quarters.
Barrett Asset Management's AstraZeneca position peaked at $24K in Q2 2020.
982 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2022.

Based on Barrett Asset Management's 13F filing for Q1 2022, filed 16 May 2022.